Sanofi (NASDAQ:SNY) Holdings Lifted by Hsbc Holdings PLC

Hsbc Holdings PLC grew its holdings in shares of Sanofi (NASDAQ:SNY) by 2,735.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 279,981 shares of the company’s stock after buying an additional 270,108 shares during the period. Hsbc Holdings PLC’s holdings in Sanofi were worth $13,661,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Boston Partners raised its stake in Sanofi by 0.3% during the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after acquiring an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares in the last quarter. Mondrian Investment Partners LTD lifted its holdings in Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the period. Envestnet Asset Management Inc. grew its position in Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after buying an additional 246,224 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in Sanofi by 26.5% during the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after buying an additional 673,172 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Down 1.1 %

SNY stock opened at $57.63 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market cap of $145.96 billion, a PE ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97. The firm has a 50 day simple moving average of $54.34 and a 200 day simple moving average of $50.50.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.95 EPS. Equities research analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research analyst reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.